Ryoncil Revenue Growth Highlighted in AGM Trading Update
Filed with ASX · · 2 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallMelbourne, Australia; November 25 and New York, USA; November 24, 2025: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided a trading update, together with a comprehensive operational overview, as part of the Chief Executive’s Annual General Meeting (AGM) address. For the quarter ending December 31, 2025, management exp
In the deck
Story so far
Earlier from Mesoblast
- CEO Presentation to 2025 Annual General Meeting
- Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
- Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
- James M. O’Brien Appointed Chief Financial Officer at Mesoblast
- Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
Later from Mesoblast
- Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
- Mesoblast Participation at Piper Sandler Conference
- Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
- Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
- Mesoblast Enters into Non-Dilutive Lower Cost 5-Year Credit
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast